Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 16/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16496110 | 0.91 | CTSA (0.58) | CTSAMEN1RAB9AKMT2AMAPT | |
| SCHEMBL16496158 | 0.89 | CTSA (0.61) | CTSA | |
| SCHEMBL16495975 | 0.87 | BAZ2B (0.52) | CTSAMAPTBAZ2B | |
| SCHEMBL16496079 | 0.86 | UTS2R (0.48) | MAPTTHRBBAZ2B | |
| SCHEMBL16496091 | 0.82 | GAA (0.51) | CTSAMAPTTHRBBAZ2B | |
| SCHEMBL12499009 | 0.80 | CTSA (0.65) | CTSA | |
| SCHEMBL12499005 | 0.80 | CTSA (0.65) | CTSA | |
| SCHEMBL16495976 | 0.80 | DCAF1 (0.46) | CTSABAZ2B | |
| SCHEMBL16495987 | 0.80 | CTSA (0.48) | CTSA | |
| SCHEMBL28601296 | 0.79 | BAZ2B (0.58) | CTSAMEN1KMT2ABAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | CTSA 1235/4885MEN1 2257/4885RAB9A 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.